TRADERPUNKAI-generated research. Not investment advice.TraderPunk is operated by Clickable Company Limited.
PerformanceTermsPrivacyDisclaimerSupport© 2026
Skip to content
TRADERPUNK
StocksPerformancePricingSample report
NYSE · Financials · Banks - Diversified

JPM

JPMorgan Chase & Co.

Universal bank spanning consumer deposits and cards, commercial lending, investment banking and asset management.

$362.84-0.07%
Close · 2026-08-14
Current callSubscribers2026-08-14
$280$300$320$340$360
NovFebMayAug
Market context
$276.43
$366.5052-week range, last close at 96% of the range
1W
+1.49%
1M
+4.59%
3M
+22.38%
6M
+21.08%
YTD
+14.21%
1Y
+25.71%
Avg vol 20d
6.6M
RVOL
0.77
HOLD band
Fundamentalsas of 2026-08-14
Mkt cap
$964.5B
P/E
15.5
Fwd P/E
14.5
EPS
$23.35
Div yield
1.65%
Beta
0.98
Employees
320.56K
Next earnings
2026-10-13
Rating & verdict historyoldest → newest
  1. ✗
  2. ✓
  3. ✗
  4. ✓
  5. ✗
  6. ✓
DateCallOutcomeReturnTakeaway
2026-08-14Subscribers——Subscribe to read
2026-08-13Subscribers——Subscribe to read
2026-08-12Subscribers——Subscribe to read
2026-08-11Subscribers——Subscribe to read
2026-08-10Subscribers
±1.15%
  • 50.0% correct+0.38% avg moveBUY 0/0 · HOLD 3/3 · SELL 0/3

    —
    —
    Subscribe to read
    2026-08-07HOLD✓+0.63%Maintain JPM at market weight with Hold rating, avoiding pre-CPI or pre-Q3 earnings directional bets despite asymmetric risk/reward math. Position sizing remains smaller than usual; use defined re-engagement triggers at $363.53 upside breakout with volume >7M and $332 50 SMA pullback for tiered adds. Q3 earnings mid-October is the mandatory reassessment gate regardless of price action.
    2026-08-06SELL✗+0.34%Underweight rating with a modest 10% position trim at $356, reducing concentration while maintaining core long-term exposure to this franchise compounder. Stop loss set at $331 (50 SMA structural support), with intermediate review trigger at $345 weekly close for potential additional 25% trim. Re-engagement gated on breakout above $362.81 with momentum confirmation, with Q3 earnings in mid-October serving as mandatory full reassessment point.
    2026-08-05HOLD✓-0.82%Maintain JPM at market weight as Hold is the mandated rating at $359 (99th percentile of 52-week range, 15.8% above 200 SMA, RSI 66), with a re-entry zone at $340-347 on a pullback and a hard stop at $330; Q3 earnings in mid-October is the mandatory reassessment gate where franchise quality (17.8% ROE, $48B capital return, 14.4x fwd P/E) will either validate continued holding or trigger a reassessment of the technical setup.
    2026-08-04SELL✗+0.48%JPM is rated Underweight with a 25% trim of the overweight position into the $360-363 zone to establish a true (non-maximum) underweight, while retaining ~75% of the core position. The trim is supported by a P/B of 2.69x (the most stretched in the series), MACD histogram flipping negative at new highs, ATR expanding to 7.46, and Dimon's fiduciary warning on S&P 500 and Treasuries. A hard stop is set at $370 (above the upper Bollinger band and outside the 1-ATR noise buffer), with tiered re-entry laddered at $348-351, $339-342, and $329-332 on confirmed 50 SMA test and positive MACD histogram. Q3 earnings in mid-October is the mandatory reassessment gate.
    2026-08-03HOLD✓+1.38%Analysts recommend maintaining JPM at benchmark or modestly below weight despite strong fundamentals (17.8% ROE, $428B retained earnings) because current valuation (P/B 2.65x, 75% above 10-year median) and momentum (MACD bearish cross at -0.37, stock ~2% from 52-week high) present unfavorable risk/reward at ~4% upside to $365-370 versus ~12% downside to $310-315. The Q3 earnings in mid-October is the mandatory reassessment point; until then, use any strength toward $357-360 as a trim opportunity (~25-30%) rather than a chase zone.
    2026-07-31SELL✗+0.24%Trim approximately 30% of JPM exposure into the $355-360 retest zone, holding the remaining ~70% core position with a structural stop at $329 (50 SMA/BB lower band confluence). Re-enter on pullbacks to $309-327 with technical confirmation or a confirmed breakout above $359.30 on volume exceeding 8M with MACD turning positive. Q3 earnings in mid-October represents the next major catalyst gate.